Search research articles
Contact Us
Filters
Showing results (31-40 of 246) with videos related to
Page
of 25
Sort By:
Mediterranean Journal of Rheumatology
|
July 18, 2020
Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
Puja Mehta, Peter C Taylor
The Lancet. Rheumatology
|
January 17, 2024
Treating to target or treating the patient in rheumatoid arthritis?
Peter C Taylor, Janet Pope
Materials (Basel, Switzerland)
|
September 13, 2025
Chemical Interactions of Deicing Salts with Concrete Pastes Containing Slag Cement
Mohsen Torabi, Peter C Taylor
Best Practice & Research. Clinical Rheumatology
|
February 1, 2020
When the first visit to the rheumatologist is established rheumatoid arthritis
Peter C Taylor, Shing T Law
Pathology
|
May 2, 2016
Actinotignum (formerly Actinobaculum) schaalii: a review of MALDI-TOF for identification of clinical isolates, and a proposed method for presumptive phenotypic identification
Robert P Stevens, Peter C Taylor
Mediterranean Journal of Rheumatology
|
June 12, 2020
SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
Shing T Law, Peter C Taylor
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 11, 2014
Combination cytokine blockade: the way forward in therapy for rheumatoid arthritis?
Peter C Taylor, Richard O Williams
Pharmacological Research
|
October 21, 2019
Role of biological agents in treatment of rheumatoid arthritis
Shing T Law, Peter C Taylor
Rheumatology (Oxford, England)
|
June 10, 2019
Rheumatoid arthritis and the emergence of immuno-autonomics
Peter C Taylor, Andrew J Holman
Nature Clinical Practice. Rheumatology
|
January 18, 2007
Etanercept plus sulfasalazine: added value in rheumatoid arthritis?
Benjamin A C Fisher, Peter C Taylor
Page
of 25
Search research articles
Search
Showing results (31-40 of 246) with videos related to
Sort By:
Page
of 25
Mediterranean Journal of Rheumatology
|
July 18, 2020
Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
Puja Mehta, Peter C Taylor
The Lancet. Rheumatology
|
January 17, 2024
Treating to target or treating the patient in rheumatoid arthritis?
Peter C Taylor, Janet Pope
Materials (Basel, Switzerland)
|
September 13, 2025
Chemical Interactions of Deicing Salts with Concrete Pastes Containing Slag Cement
Mohsen Torabi, Peter C Taylor
Best Practice & Research. Clinical Rheumatology
|
February 1, 2020
When the first visit to the rheumatologist is established rheumatoid arthritis
Peter C Taylor, Shing T Law
Pathology
|
May 2, 2016
Actinotignum (formerly Actinobaculum) schaalii: a review of MALDI-TOF for identification of clinical isolates, and a proposed method for presumptive phenotypic identification
Robert P Stevens, Peter C Taylor
Mediterranean Journal of Rheumatology
|
June 12, 2020
SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
Shing T Law, Peter C Taylor
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 11, 2014
Combination cytokine blockade: the way forward in therapy for rheumatoid arthritis?
Peter C Taylor, Richard O Williams
Pharmacological Research
|
October 21, 2019
Role of biological agents in treatment of rheumatoid arthritis
Shing T Law, Peter C Taylor
Rheumatology (Oxford, England)
|
June 10, 2019
Rheumatoid arthritis and the emergence of immuno-autonomics
Peter C Taylor, Andrew J Holman
Nature Clinical Practice. Rheumatology
|
January 18, 2007
Etanercept plus sulfasalazine: added value in rheumatoid arthritis?
Benjamin A C Fisher, Peter C Taylor
Page
of 25